BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19224757)

  • 1. Herpes zoster in the age of focused immunosuppressive therapy.
    Whitley RJ; Gnann JW
    JAMA; 2009 Feb; 301(7):774-5. PubMed ID: 19224757
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?
    Bongartz T; Orenstein R
    Nat Rev Rheumatol; 2009 Jul; 5(7):361-3. PubMed ID: 19568250
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.
    Serac G; Tubach F; Mariette X; Salmon-Céron D; Ravaud P; Lioté F; Laharie D; Ziza JM; Marguerie L; Bonnet C; Falgarone G; Nicolas N; Lortholary O; Chosidow O
    J Invest Dermatol; 2012 Mar; 132(3 Pt 1):726-9. PubMed ID: 22113472
    [No Abstract]   [Full Text] [Related]  

  • 5. Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy.
    Winthrop KL; Furst DE
    Ann Rheum Dis; 2010 Oct; 69(10):1735-7. PubMed ID: 20858622
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
    Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
    Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
    Kubandova Z; Mathieu S; Pourtier C; Soubrier M
    Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
    [No Abstract]   [Full Text] [Related]  

  • 8. Protracted herpes zoster and severe postherpetic neuralgia after inadvertant infliximab administration.
    Failla V; Castronovo C; Meex C; Nikkels AF
    Eur J Dermatol; 2011; 21(5):782-3. PubMed ID: 21700542
    [No Abstract]   [Full Text] [Related]  

  • 9. Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-α.
    Javed S; Kamili QU; Mendoza N; Tyring SK
    J Med Virol; 2011 Nov; 83(11):2051-5. PubMed ID: 21915882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 14. [Serious lung disease in RA and TNF-blockade--is there a connection?].
    Turesson C; Jacobsson L; Saxne T; Geborek P
    Lakartidningen; 2006 Feb 1-7; 103(5):308; author reply 308-9. PubMed ID: 16512575
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic listeriosis with adalimumab therapy.
    Murphy G; Schmidt-Martin D; Hynes BG; Harney S
    J Clin Rheumatol; 2009 Oct; 15(7):369-70. PubMed ID: 20009978
    [No Abstract]   [Full Text] [Related]  

  • 16. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
    Bendtzen K
    Arthritis Rheum; 2011 Apr; 63(4):867-70. PubMed ID: 21452309
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K; Weinberg JM
    J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
    Gabriel SE
    Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.